This federal Project Grant award from the National Institute of Neurological Disorders and Stroke (NINDS), under the Extramural Research Programs in the Neurosciences and Neurological Disorders (CFDA 93.853) program, provides $665,171 to support research aimed at improving outcomes for individuals with HIV-associated opportunistic infections, such as cryptococcal and TB meningitis. The 5-year grant, awarded on August 18, 2024, will fund a collaborative effort led by the Regents of the University of Minnesota to:
- Define cerebrospinal fluid drug concentrations or exposure metrics that predict pathogen clearance rates;
- Determine the relationship between cerebrospinal fluid drug levels and clinical outcomes like inflammation, resistance, neurocognitive function, and survival; and
- Evaluate drug distribution in brain tissue using post-mortem specimens.
This project builds on prior research by the University of Minnesota and its partners, including the Infectious Diseases Institute (IDI) in Uganda, which will serve as a sub-awardee. The findings are expected to enhance understanding of drug pharmacokinetics and pharmacodynamics in the central nervous system, in order to optimize treatment regimens and ultimately reduce mortality from these HIV-associated infections.
Generated 1/28/25, 9:04 AM